Oncolytics is incorporated in Alberta, Canada.
Oncolytics’ corporate headquarters are located at Suite 804, 322 – 11th Avenue SW, Calgary, Alberta, Canada, T2R 0C5.
Oncolytics’ fiscal year-end is December 31st.
Oncolytics’ independent registered public accounting firm is Ernst & Young, LLP.
Oncolytics’ common shares can be bought and/or sold through a stockbroker, bank or any other financial institution that provides brokerage services.
Oncolytics does not pay dividends.
The CUSIP number of Oncolytics’ common stock is 682310.
Oncolytics’ transfer agent is AST Trust Company.
AST Trust Company (Canada)
PO Box 700, Station B
Montreal, Quebec H3B 3K3
F: 1.888.249.6189 (in North America); 514.985.8843 (outside North America)
US Warrant holders:
To change your address on your stockholder account, contact Oncolytics’ transfer agent, AST Trust Company. Contact information is available on our IR Contacts page.
You may review a copy of Oncolytics’ annual or periodic reports by clicking here.
Oncolytics is traded on the Toronto Stock Exchange (TSX) under the symbol “ONC”, and on the Nasdaq Capital Market under the symbol “ONCY”.
There is no need to replace lost stock certificates. Following Oncolytics’ initial public offering, all physical stock certificates were deemed void and the shares represented by the stock certificates were reflected in an electronic book entry account set up for you with our transfer agent, AST Trust Company. For questions about how many shares you hold, please contact AST. Contact information is available on our IR Contacts page.
If your address changes, please notify Oncolytics’ transfer agent, AST Trust Company. Contact information is available on our IR Contacts page.
Oncolytics went public on November 8, 1999.
Oncolytics was founded in 1998.
For media inquiries, please contact Jon Patton, Director of Investor Relations & Communication at email@example.com.
For investor relations inquiries, please contact Jon Patton, Director of Investor Relations & Communication at firstname.lastname@example.org.
You may sign up to receive Oncolytics’ press releases and other company information here.
You may contact Oncolytics at (403) 670-7377 or email@example.com.
Ernst & Young LLP
215 2nd St. SW, Suite 2200
Calgary, AB T2P 1M4
McCarthy Tetrault LLP
421 7th Ave SW, Suite 3300
Calgary, AB T2P 4K9